Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial

被引：0

作者：

Kim, H. ^{[1
]}

Park, S. ^{[2
]}

Kim, T. M. ^{[3
]}

Han, J-Y. ^{[4
]}

Lee, G-W. ^{[5
,6
]}

Shim, B. Y. ^{[7
]}

Lee, Y-G. ^{[8
]}

Kim, S-W. ^{[9
]}

Ock, C-Y. ^{[10
]}

Hwang, S. ^{[11
]}

Lee, Y. ^{[12
]}

Kim, R. ^{[13
]}

Jung, H. A. ^{[14
]}

Sun, J-M. ^{[15
]}

Lee, S-H. ^{[16
]}

Ahn, J. S. ^{[15
]}

Ahn, M-J. ^{[17
]}

机构：

[1] Samsung Med Ctr SMC, Hematooncol, Seoul, South Korea

[2] Samsung Med Ctr SMC, Hematol & Med Oncol, Seoul, South Korea

[3] Seoul Natl Univ, Internal Med Dept, Coll Med, Yeongeon Med Campus, Seoul, South Korea

[4] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Ctr Lung Canc, Goyang, South Korea

[5] Gyeongsang Natl Univ Hosp, Internal Med Dept, Jinju, South Korea

[6] Gyeongsang Natl Univ, Sch Med, Jinju, South Korea

[7] Catholic Univ Korea, Dept Internal Med, St Vincents Hosp, Suwon, South Korea

[8] Kangbuk Samsung Hosp, Samsung Med Ctr SMC, Dept Internal Med, Seoul, South Korea

[9] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea

[10] Lunit Inc, Med Affairs, Oncol Grp, Seoul, South Korea

[11] Lunit, Med Affairs, Oncol Grp, Seoul, South Korea

[12] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea

[13] Inocras, Oncol Dept, San Diego, CA USA

[14] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Div Hematol Oncol,Dept Med, Seoul, South Korea

[15] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Dept Med, Seoul, South Korea

[16] Samsung Med Ctr SMC, Med Oncol, Seoul, South Korea

[17] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr SMC, Hematol Oncol Dept, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

631P

引用

页码：S1636 / S1636

页数：1

共 50 条

[21] A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis
Han, B.
Tian, P.
Zhao, Y.
Yu, X.
Guo, Q.
Yu, Z.
Zhang, X.
Li, Y.
Chen, L.
Shi, X.
Zhang, Y.
Wang, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1443 - S1444
[22] Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS).
Lu, Shun
Dong, Xiaorong
Jian, Hong
Chen, Jianhua
Chen, Gongyan
Sun, Yuping
Ji, Yinghua
Wang, Ziping
Shi, Jianhua
Lu, JunGuo
Chen, Shaoshui
Lv, Dongqing
Zhang, Guojun
Liu, Chunling
Li, Juan
Yu, Xinmin
Lin, Zhong
Yu, Zhuang
Wang, Zhehai
Cui, Jiuwei
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[23] Letter regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
Hatanaka, Takeshi
Hiraoka, Atsushi
Tada, Toshifumi
Kakizaki, Satoru
LIVER CANCER, 2024, 13 (06) : 669 - 670
[24] Circulating free DNA as a prognostic biomarker in patients with advanced ALK plus NSCLC treated with alectinib from the global phase III ALEX trial.
Dziadziuszko, Rafal
Peters, Solange
Mok, Tony S. K.
Camidge, D. Ross
Noe, Johannes
Nowicka, Malgorzata
Bordogna, Walter
Morcos, Peter N.
Smoljanovic, Vlatka
Tsang, Alice
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
Furuya, Naoki
Watanabe, Satoshi
Nakamura, Atsushi
Shiihara, Jun
Nakachi, Ichiro
Tanaka, Hisashi
Nakao, Mika
Minato, Koichi
Seike, Masahiro
Sasaki, Shinichi
Kisohara, Akira
Takeuchi, Susumu
Honda, Ryoichi
Takamura, Kei
Kagamu, Hiroshi
Yoshimura, Kenichi
Kikuchi, Toshiaki
Kobayashi, Kunihiko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[26] A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naive Patients with EGFRm plus NSCLC: Exploratory Biomarker Analysis
Wang, J.
Zhao, J.
Bai, H.
Wang, X.
Wang, Y.
Duan, J.
Chen, H.
Xue, Z.
Meng, S.
Tian, Y.
Cseh, A.
Huang, D. C.
Wu, Y.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1050 - S1051
[27] Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
Macarulla, Teresa
Ren, Zhenggang
Chon, Hong Jae
Park, Joon Oh
Kim, Jin Won
Pressiani, Tiziana
Li, Daneng
Zhukova, Lyudmila
Zhu, Andrew X.
Chen, Ming-Huang
Hack, Stephen P.
Wu, Stephanie
Liu, Bo
Guan, Xiangnan
Lu, Shan
Wang, Yulei
El-Khoueiry, Anthony B.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (05)
[28] Bevacizumab plus erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial
Piccirillo, M. C.
Bonanno, L.
Garassino, M. C. C.
Dazzi, C.
Cavanna, L.
Esposito, G.
Burgio, M. A.
Rosetti, F.
Rizzato, S.
Arenare, L.
Gargiulo, P.
Di Liello, R.
De Marinis, F.
Crino, L.
Morgillo, F.
Ciardiello, F.
Normanno, N.
Gallo, C.
Gridelli, C.
Morabito, A.
ANNALS OF ONCOLOGY, 2021, 32 : S950 - S950
[29] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
Kudo, Masatoshi
Tsuchiya, Kaoru
Yamashita, Tatsuya
Koga, Hironori
Nakagawa, Yuki
Ikeda, Masafumi
LIVER CANCER, 2024, 13 (06) : 671 - 673
[30] A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
Watanabe, Satoshi
Furuya, Naoki
Nakamura, Atsushi
Shiihara, Jun
Nakachi, Ichiro
Tanaka, Hisashi
Nakao, Mika
Minato, Koichi
Seike, Masahiro
Sasaki, Shinichi
Kisohara, Akira
Takeuchi, Susumu
Honda, Ryoichi
Takamura, Kei
Kagamu, Hiroshi
Yoshimura, Kenichi
Kobayashi, Kunihiko
Kikuchi, Toshiaki
EUROPEAN JOURNAL OF CANCER, 2024, 197

← 1 2 3 4 5 →